Recon: AstraZeneca seeks EUA for preventative COVID antibody; EMA considers rolling review for Merck's COVID drug

• Pfizer/BioNTech COVID-19 vaccine effectiveness drops after 6 months, study shows (Reuters)
• J&J files for authorization of COVID-19 vaccine booster (Reuters)
• AstraZeneca Submits Preventive Covid-19 Treatment for FDA Authorization (WSJ) (Reuters)
• Pharmacy chains failed to prevent opioid misuse, U.S. jury hears (Reuters)
• Henrietta Lacks' estate says pharma company profited from stolen cells (Reuters)
• Eli Lilly’s recalled emergency diabetes drug came from plant cited by FDA (Reuters)
• Rapid COVID-19 tests increasingly scarce, pricey as demand from employers jumps (Reuters)
• Feds accuse AstraZeneca of underpaying 318 female and Hispanic employees (Endpoints)
• NIH Director Francis Collins to step down (STAT)

• EMA to consider rolling review for Merck's molnupiravir in coming days (Reuters)
• Europe’s drug regulator said a booster shot of the Pfizer-BioNTech vaccine could be given to healthy adults. (NYTimes)
• NICE recommends first new sickle cell disease treatment in 20 years (Pharmafile)
• Norway to offer COVID vaccine booster to those aged 65 and older (Reuters)

• GlaxoSmithKline abandoning iconic US HQ space in a shift inspired by the new normal (Endpoints)
• Innovative Licensing and Access Pathway (ILAP): New partner announcement (MHRA)
• Aduhelm In Medicaid: States Must Cover, CMS Official Says (Pink Sheet)
• Gang of 7: Boehringer joins group of companies targeted over drug discount program (Endpoints)
• Gemini axes CSO and 20% of staff to focus on late-phase plans (Fierce)
• Vedanta brings home a win for lead microbiome program, passing a PhII test and clinching BARDA investment (Endpoints)
• Ex-FDA officials ask SCOTUS to take up J&J talc case; Annovis shows data from PhII Parkinson's trial (Endpoints)
• A month after a manufacturing hiccup led to a CRL, CorMedix CEO will retire (Endpoints)
• Medicxi co-founder David Grainger gets his other foot in Centessa's door as chief innovation officer (Endpoints)
• New small molecule player with roots in David Liu's lab collects another $78M to fuel search for exosites (Endpoints)
• iOmx refuels with $75M+ on its search for immune checkpoint targets on tumor cells (Endpoints)

• MCIT, cyber, RWE and 3 more takeaways from AdvaMed's 2021 conference (MedtechDive)
• Hologic begins broad European launch of its tabletop Novodiag tester after its $795M acquisition (Fierce)
• EU Classification ‘Bible’ Published To Support Risk Class Decision-Making (MedtechInsight)

• J&J Unit Must Face Claims Pelvic Mesh Was Defective (Law360)
• Drugmakers In Zantac MDL Try To Trim Claims (Law360)